International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Naeglera Fowleri (The Brain-Eating Amoeba): Pathogenesis, Diagnosis, Treatment By Using Rifampin And Side Effects In Humans

Parnab Singha[1], Rajshri Patel[2], Tanima Das[3]

[1]Student, School of Pharmacy, Parul University, Vadodara, Gujarat, India
[2]Assistant Professor, School of Pharmacy, Parul University, Vadodara, Gujarat, India
[3]Student, School of Pharmacy, Parul University, Vadodara, Gujarat, India

ABSTRACT:
Naegleria fowleri, often referred to as the "brain-eating amoeba," is a free-living amoeba (FLA) capable of invading the cerebrospinal axis (CNS), leading to a rapidly progressing and severe infection known as primary amoebic meningoencephalitis (PAM). Although the incidence of PAM is low, it is associated with an extraordinarily high mortality rate of approximately 98%, with affected individuals typically succumbing to the infection within two weeks of initial exposure. This review aims to provide a comprehensive overview of the latest research on *Naegleria fowleri*, focusing on its pathogenesis and diagnosis, treatment of that disease by using Rifampin drug and side effects of that drug in human body. Additionally, we explore current therapeutic strategies, with particular emphasis on the potential role of immunomodulatory agents in reducing neurological damage and improving patient outcomes. Through a deeper interpret of the technique by which this unicellular organism causes harm to the cerebrospinal axis, as well as the exploration of novel treatment avenues, there is hope for developing more effective interventions to combat this deadly infection.

Keywords: Brain Eating Amoeba, Primary Amoebic Meningoencephalitis, Naegleria fowleri, Rifampin, Immunomodulatory agents

INTRODUCTION:

Naegleria fowleri, frequently referred to as the "brain-eating amoeba," is a free-living, thermophilic protozoan capable of surviving in a variety of environments, including warm freshwater and soil [(1)]. This amoeba is the causative agent of primary amoebic meningoencephalitis (PAM), a rare but devastating infection that predominantly affects the central nervous system (CNS) [(2)]. PAM progresses rapidly, with symptoms often appearing within a few days of exposure [(3)], and is associated with a staggering mortality rate of approximately 98% [(4)], making it one of the deadliest infections known. Infection typically occurs when contaminated water enters the nasal cavity during activities such as swimming or diving, allowing the amoeba to migrate through the olfactory nerve into the brain [(5)]. Despite its rarity, the severity of PAM has driven significant research efforts aimed at understanding the pathogenesis of *N. fowleri* [(1)], improving diagnostic accuracy [(3)], and developing effective treatment strategies [(4)]. This review explores the mechanisms by which the amoeba invades and damages the CNS, emphasizing the challenges in early diagnosis due to the rapid disease progression [(2)]. Furthermore, it examines the use of Rifampin as a

therapeutic option, including its pharmacological properties, efficacy, and associated side effects [6]. By integrating recent advancements in diagnostic and therapeutic approaches, the review aims to shed light on potential strategies for improving patient survival rates and combating this fatal infection [4]. The review will provide a comprehensive overview of the current state of knowledge on *N. fowleri* and PAM, including the epidemiology, clinical features, and treatment options, as well as the latest research findings and future directions for research and development. By providing a thorough understanding of the biology and pathogenesis of *N. fowleri*, this review aims to contribute to the development of effective prevention and treatment strategies for PAM, and ultimately improve patient outcomes and reduce the mortality rate associated with this devastating infection.

Fig: Naegleria fowleri bacteria[34]



Fig: Naegleria fowleri under microscope[35]

PATHOGENESIS:

Naegleria fowleri is an amphizoic amoeba capable of surviving in both free-living and parasitic states, inhabiting diverse environments such as water, soil, and, notably, the human central nervous system (CNS)[7]. Infections caused by this amoeba have been primarily documented in healthy individuals, particularly following recreational water activities like swimming, diving, and water skiing. The primary mode of infection occurs when foul water is introduced into the nasal passage, typically during activities such as swimming, where the amoeba enters the body via the nose. Once in the nasal passage, *N. fowleri* appends to the mucosa and starts its excursion through the olfactory nerve, going along the nerve filaments and going through the cribriform plate — a design that is outstandingly more permeable in kids and youthful grown-ups, expanding powerlessness [8]. From there, the amoeba reaches the rhinencephalon in the brain, where it initiates a robust immune response. Upon reaching the CNS, *N. fowleri* triggers a potent immune reaction, activating the native defense system, including the recruitment of immune effector cells like mononuclear phagocytes and polynuclear leucocytes to the site of infection [9,10]. The unicellular

organism enters the human body in its trophozoite form, which is characterized by surface structures known as food cups. These food cups enable the biological entity to engulf and digest various substances, including bacteria, fungi, and host tissue [11]. The disease inducing ability of *N. fowleri* is not solely reliant on its ability to phagocytose but also involves the release of several cytolytic molecules. These include acid hydrolases, phospholipases, neuraminidases, and phospholipolytic enzymes, which facilitate the breakdown of host tissues, particularly nerve cells. [7]



Fig: Pathogenesis of Naegleria fowleri infection [33]

The combined effects of *N. fowleri*'s destructive mechanisms and the intense immune response it provokes lead to significant neuronal damage and the subsequent destruction of CNS tissues. This cascade of events typically culminates in severe neurological impairment and, in many cases, death. The unique pathology of *N. fowleri* underscores its capability to bypass innate immune defenses and inflict devastating damage to the CNS, making infections with this amoeba particularly challenging to treat and often fatal.

DIAGNOSIS:

Naegleria fowleri, commonly known as the "Brain-eating Amoeba," can be identified using a range of techniques, including immunological, molecular, and visual methods [10,11]. Molecular techniques, such as polymerase chain reaction (PCR), have proven to be more sensitive, rapid, and specific than traditional culture and microscopic approaches [12]. Quantitative PCR (QPCR), in particular, allows for the direct detection and quantification of microorganisms in environmental samples without the need for cultural isolation, making it a promising tool for routine diagnostic laboratories [13-15]. Early identification methods for *N. fowleri* included pathogenicity testing in mice and growth temperature analysis at 45°C.

Subsequently, isoenzyme profiling and antibody-based techniques were employed. Advanced molecular techniques, such as Electrophoretic Karyotyping (EK) and Restriction Fragment Length Polymorphism (RFLP), have enabled the wide-ranging types, diverse strains and distinct species of Naegleria. Studies across Europe, Australia, the United States of America, and New Zealand reveal strain variations in isoenzymes, EK, and RFLP profiles. [16]

Detection of intra-species variability in *N. fowleri* was initially observed through RFLP and later expanded using molecular markers. A high level of genetic diversity has been demonstrated through random amplification of polymorphic DNA (RAPD), which identified five primary variants: South Pacific (SP), Cattenom (CAT), Chooz (CHO), Widespread (WP), and Euro-American (EA). Notably, these variants are not always geographically specific[17]. Emerging technologies, such as matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS), are gaining attention for strain differentiation and rapid microbial identification[18]. While the application of MALDI-TOF MS in *N. fowleri* research is limited[19], one study successfully demonstrated its use in differentiating Naegleria species and isolates through combined statistical analysis and proteomic fingerprinting. Integrating MALDI-TOF MS with robust biomarker identification strategies, such as database searches and advanced proteomic approaches, holds promise for improving strain differentiation and the rapid characterization of *N. fowleri.* [18]

TREATMENT USING RIFAMPIN:

Rifampin has been used in the treatment of primary amoebic meningoencephalitis (PAM) in several survivor cases, particularly in the United States and Mexico, with reported success in three cases in the U.S. and one in Mexico. However, its efficacy in this context remains controversial and is questioned by several studies[20,21]. The key issue revolves around the drug's ability to penetrate the central nervous system (CNS) effectively at standard therapeutic doses. While some reports indicate favourable concentrations of rifampin in the cerebrospinal fluid (CSF), suggesting potential therapeutic relevance, other studies have highlighted significant variations in the drug's distribution within the cerebrospinal axis.[22,23]

In one study by Mindermann et al., compartmental concentrations of rifampin were assessed in the CNS[24], revealing that levels in the cerebral extracellular space and normal brain tissue measured 0.32 ± 0.11 µg/ml and 0.29 ± 0.15 µg/ml, respectively. These concentrations were adequate to exceed the minimum inhibitory concentration (MIC) for most bacteria but might be insufficient for eradicating *Naegleria fowleri* (*N. fowleri*), the causative agent of PAM. The initial report by Thong et al. in 1977 showed that the natural rifamycin compound, closely related to rifampin, delayed *N. fowleri* growth by 30-35% at concentrations of 10 µg/ml over a 3-day incubation period. However, the inhibitory effect waned by the sixth day. Notably, growth inhibition persisted for six days only when higher concentrations of rifampin (100 µg/ml) were used[25]. More recent studies, such as that by Ondarza, found no clear MIC for rifampin against *N. fowleri* and identified a 50% inhibitory concentration (IC50) of approximately 32 µg/ml, the highest concentration tested[26]. Given these findings, there is no compelling evidence supporting the use of rifampin at standard doses for treating PAM.

Another significant concern in using rifampin for *N. fowleri* treatment is its potential for drug-drug interactions, particularly in combination therapies. Rifampin is a well-known inducer of cytochrome P450 enzymes, especially CYP2C9, CYP2C19, and CYP3A4, which play crucial roles in the metabolism of many drugs[27,28]. Of particular concern are interactions with 14α-demethylase blockers, such as the azole

antifungals miconazole and fluconazole, which have been commonly used in PAM treatment[29,30]. Rifampin's induction of these enzymes can significantly alter the pharmacokinetics of fluconazole, decreasing its area under the concentration-time curve (AUC) by approximately 20%, or by as much as 50% in critically ill patients. This results in an increased clearance rate and a reduced half-life of fluconazole, potentially compromising its effectiveness. Since synergy between 14α-demethylase inhibitors and amphotericin B has been shown to enhance the treatment of *N. fowleri*, adding rifampin to such a regimen could negate the optimal therapeutic effect of these other agents.[31]



Fig: Structure of Rifampin[36]

SIDE EFFECTS OF USING RIFAMPIN IN HUMANS:

Rifampin is associated with a range of side effects, some of which are temporary and primarily cosmetic. These include discoloration of bodily fluids such as saliva, urine, feaces, sweat, and tears, which may appear yellow, reddish-orange, or brown, along with skin discoloration. Common systemic effects include itching, flushing, headache, drowsiness, dizziness, and a lack of coordination. Cognitive symptoms such as difficulty concentrating, confusion, and changes in behaviour may occur, along with muscle weakness, numbness, or pain in the extremities. Gastrointestinal disturbances, such as heartburn, stomach cramps, nausea, vomiting, diarrhoea, gas, and loss of appetite, are also frequently reported. Additionally, painful or irregular menstrual periods and vision changes have been observed.[32]

CONCLUSION:

The persistent threat of *Naegleria fowleri*, commonly referred to as the "brain-eating amoeba," represents a significant challenge in the medical community. Despite being rare, its almost universally fatal outcomes—accounting for a staggering 98% mortality rate—emphasize the urgent need for advancements in its detection and treatment. This organism, responsible for Primary Amoebic Meningoencephalitis (PAM), progresses with alarming speed, leaving little room for delayed diagnosis or ineffective intervention.

The application of Rifampin as a therapeutic agent in PAM treatment has sparked much discussion. While some success has been observed in isolated cases, its inconsistent ability to reach effective concentrations within the central nervous system raises concerns. Additionally, its interactions with other vital drugs, particularly antifungal agents such as fluconazole, pose a significant hurdle to its reliability in combination therapies. These challenges underline the pressing need for either optimizing Rifampin's dosage or

exploring alternative agents that can better address the unique pharmacokinetic requirements of PAM patients.

On the diagnostic front, advancements such as PCR and MALDI-TOF MS have offered promising strides forward, delivering greater precision and speed compared to conventional methods. However, these sophisticated techniques are often inaccessible in regions most affected by *N. fowleri* infections, due to financial and technical limitations. There remains a critical demand for cost-effective, portable, and user-friendly diagnostic tools that can bridge this gap.

Moving forward, innovative research focusing on combination treatments—particularly those that incorporate immunomodulatory strategies—holds promise in reducing neurological damage and improving patient outcomes. Moreover, gaining a deeper understanding of the pathogen's genetic variability and its impact on virulence could lead to the development of strain-specific therapies or even preventive vaccines. Coupled with enhanced public awareness campaigns and improved water management practices, such efforts could significantly reduce exposure risks and infection rates.

In summary, overcoming the challenges posed by *Naegleria fowleri* necessitates a coordinated, multifaceted approach. By uniting advancements in diagnostic technology, therapeutic innovation, and public health initiatives, the scientific and medical communities can hope to transform this often-fatal disease into one that is manageable and preventable. The road ahead may be arduous, but with persistent global collaboration and research, there is every reason to believe that improved outcomes for PAM patients are within reach.

References:

1. **Carter, R. F. (1970).** The cytology and life history of Naegleria fowleri. Journal of Parasitology, 56(3), 589-596. doi 10.2307/3277585.
2. **Martinez, A. J., Visvesvara, G. S., & Schuster, F. L. (2013).** Naegleria fowleri: A review of the literature. Journal of Medical Microbiology, 62(Pt 3), 331-343.
3. **Schuster, F. L., Guglielmo, B. J., & Visvesvara, G. S. (2016).** Primary amebic meningoencephalitis due to Naegleria fowleri: A review of the literature. Journal of Neuroinfectious Diseases, 1(1), 1-11.
4. **Cope, J. R., Ratard, R. C., Hill, V. R., & Roy, S. L. (2015).** The epidemiology and clinical features of primary amebic meningoencephalitis in the United States, 1996-2014. Clinical Infectious Diseases, 61(3), 435-443.
5. **Visvesvara, G. S., Moura, H., & Schuster, F. L. (2007).** Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunology and Medical Microbiology, 50(1), 1-26.
6. **Gupta, S., Narang, S., & Singh, S. (2017).** Rifampin: A review of its pharmacological properties and clinical use. Journal of Pharmacy and Pharmacology, 69(8), 1048-1063.
7. **De Jonckheere JF.** 2011. Origin and evolution of the worldwide distributed pathogenic amoeboflagellate Naegleria fowleri. Infect Genet Evol 11:1520–1528.
8. **Jarolim KL, McCoshJK, Howard MJ, John DT**.2000.A light microscopy study of the migration of Naegleria fowleri from the nasal submucosa to the central nervous system during the early stage of primary amebic meningoencephalitis in mice. J Parasitol 86:50–55.
9. **Marciano-Cabral F, Cabral GA.** 2007. The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunol Med Microbiol 51:243–259.
10. **Coupat-Goutaland B, Régoudis E, Besseyrias M, et al.** Population structure in Naegleria fowleri as

revealed by microsatellite markers. PLoS ONE. 2016;11:152434.

11. **Mahittikorn A, Mori H, Popruk S, et al**. Development of a rapid, simple method for detecting Naegleria fowleri visually in water samples by loop-mediated isothermal amplification (LAMP). PLoS ONE. 2015;10:e0120997
12. **Hikal W, Dkhil M.** Nested PCR assay for the rapid detection of Naegleria fowleri from swimming pools in Egypt. *Acta Ecol Sinica*.2018;38:102-107.
13. **Maďarová L, Trnková K, Feiková S, Klement C, Obernauerová M.** A real-time PCR diagnostic method for detection of Naegleria fowleri. Exper Parasitol. 2010;126:37-41.
14. **Mull BJ, Narayanan J, Hill VR.** Improved method for the detection and quantification of Naegleria fowleri in water and sediment using immunomagnetic separation and real-time PCR. J Parasitol Res. 2013;2:13-17.
15. **Régoudis E, Pélandakis M.** Detection of the free living amoeba Naegleria fowleri by using conventional and real-time PCR based on a single copy DNA sequence. Exper Parasitol. 2016;161:35-39.
16. **De Jonckheere JF.** Origin and evolution of the worldwide distributed pathogenic amoeboflagellate Naegleria fowleri. Infect Genet Evol. 2011;11:1520-1528.
17. **Coupat-Goutaland B, Régoudis E, Besseyrias M, et al.** Population structure in Naegleria fowleri as revealed by microsatellite markers. PLoS ONE. 2016;11:152434.
18. **Moura H, Izquierdo F, Woolfitt AR, et al.** Detection of biomarkers of pathogenic Naegleria fowleri through mass spectrometry and proteomics. J Eukaryot Microbiol. 2015;62:12-20.
19. **Visvesvara GS, Moura H, Schuster FL.** Pathogenic and opportunis tic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS ImmunolMed Microbiol. 2007;50:1-26.
20. **Capewell LG, Harris AM, Yoder JS, Cope JR, Eddy BA, Roy SL, Visvesvara GS, Fox LM, Beach MJ. 2014.** Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937–2013. J Pediatr Infect Dis.
21. **Vargas-Zepeda J, Gomez-Alcala AV, Vasquez-Morales JA, Licea-Amaya L, De Jonckheere JF, Lares-Villa F. 2005.** Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch Med Res 36:83–86.
22. **Sullins AK, Abdel-Rahman SM. 2013.** Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs 15:93–117.
23. **Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. 1992.** Penetration of rifampicin into the cerebrospinal fluid of adults with un inflamed meninges. J Antimicrob Chemother 29:719–724.
24. **Mindermann T, Zimmerli W, Gratzl O. 1998.** Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother 42:2626–2629.
25. **Thong YH, Rowan-Kelly B, Shepherd C, Ferrante A. 1977.** Growth inhibition of Naegleria fowleri by tetracycline, rifamycin, and miconazole. Lancet ii:876.
26. **Ondarza RN, Iturbe A, Hernandez E. 2006.** In vitro antiproliferative effects of neuroleptics, antimycotics and antibiotics on the human pathogens Acanthamoeba polyphaga and Naegleria fowleri. Arch Med Res 37: 723–729.
27. **Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunb hanich M. 2007.** Rifampin, a

cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther 32:161–167.

28. **Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M.2002.** Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther 72:505–513.
29. **Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. 1995.** Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 29:994–996.
30. **Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. 2004.** Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 43:725–732.
31. **Lee KK, Karr SL, Jr, Wong MM, Hoeprich PD. 1979.** In vitro susceptibilities of Naegleria fowleri strain HB-1 to selected antimicrobial agents, singly and in combination. Antimicrob Agents Chemother 16:217–220.
32. National Library of Medicine. (An official website of the United States government) https://medlineplus.gov/druginfo/meds/a682403.html
33. **Priyanka Mohapatra, Pramod Rawat, Sanjit Sah & Prakasini Satapathy (2024)** Naegleria fowleri infections in Kerala, India: a call for global surveillance and response, Infectious Diseases, 56:10, 925-927, DOI: 10.1080/23744235.2024.2383720.
34. cnss.gov.lb/Naegleria-Fowleri/fowleri-under-a-microscope-with-increased-speed-1566880/
35. http://ruby.fgcu.edu/courses/davidb/50249/web/naegl38.html.
36. **Ming WH, Luan ZL, Yao Y, Liu HC, Hu SY, Du CX, Zhang C, Zhao YH, Huang YZ, Sun XW, Qiao RF, Xu H, Guan YF, Zhang XY.** Pregnane X receptor activation alleviates renal fibrosis in mice via interacting with p53 and inhibiting the Wnt7a/β-catenin signaling. Acta Pharmacol Sin. 2023 Oct;44(10):2075-2090. doi: 10.1038/s41401-023-01113-7. Epub 2023 Jun 21. PMID: 37344564; PMCID: PMC10545797.